Acronym PHARMASEA
Category
Marine Biotechnology
Title Increasing Value and Flow in the Marine Biodiscovery Pipeline Programme FP7
Instrument (FP6)
Contact Type (FP7)
Strand (Interreg)
FP7 - Collaborative Project targeted to a Special Group (such as SMEs)
Theme (FP7)
Activity Area (FP6)
Regional Area (Interreg)
Action (COST)
KBBE – Food, Agriculture and Fisheries, and Biotechnology
Specific Programme (FP7)
Cooperation
Funding source European Coordinator Esguerra Camila Coordinator email camila.esguerra@pharm.kuleuven.be
Coordinator institution
KU Leuven - Catholic University of Leuven (Belgium)
Institutions involved
NA - Advanced Chemistry Development UK Ltd (United Kingdom) ,
NA - BioBridge Ltd (United Kingdom) ,
NA - BIOCOM AG (Germany) ,
NA - c-LEcta GmbH (Germany) ,
IMCAS - Chinese Academy of Sciences; Institute of Microbiology (China) ,
eCOAST - eCOAST Marine Research (Belgium) ,
NA - Fundación MEDINA (Spain) ,
ICDB - Institute for Cell Dynamics and Biotechnology (Chile) ,
INBio - Instituto Nacional de Biodiversidad (Costa Rica) ,
IUCN - International Union for Conservation of Nature (Switzerland) ,
CNR - National Research Council (Italy) ,
RSC - Royal Society of Chemistry (United Kingdom) ,
SZN - Stazione Zoologica Anton Dohrn (Italy) ,
DTU - Technical University of Denmark (Denmark) ,
UiT - The Arctic University of Norway (Norway) ,
UCC - University College Cork (Ireland) ,
UOA - University of Aberdeen (United Kingdom) ,
USC - University of Santiago de Compostela (Spain) ,
UWC - University of the Western Cape (South Africa) ,
UoW - University of Waikato (New Zealand) ,
WHU - Wuhan University (China) ,
Start year 2012 End year 2017 Funding (€) € 13,194,700 Website https://cordis.europa.eu/project/id/312184/results Summary The PharmaSea project focuses on obstacles in marine biodiscovery research, development and commercialization and brings together a broad interdisciplinary team of academic and industry researchers and specialists to address and overcome these. The partners are ideally placed to demonstrate how to widen the bottlenecks and increase the flow of ideas and products derived from the marine microbiome towards a greater number of successes in a larger number of application areas. Despite the tremendous potential of marine biodiscovery, exploitation, particularly at a commercial scale, has been hampered by a number of constraints. These relate to access (physical and legal), genetics of the organisms, compound isolation, structure elucidation, early reliable validation of biological activity and best mechanisms of flow�� through into exploitation. PharmaSea will solve these chronic bottlenecks by developing essential actions beyond the state of the art and linking them with best practice and appropriate pragmatic approaches. The robust pipeline structure established within PharmaSea will process a wide genetic basis including marine microbial strain collections held by partners and new strain collections from extreme environments (deep, cold and hot vent habitats) to produce new products with desirable characteristics for development by the SME partners in three accessible market sectors, health (infection, inflammation, CNS diseases), personal care and nutrition. The global aim of PharmaSea is to produce two compounds at larger scale and advance them to pre��clinical evaluation. To address relevant challenges in marine biodiscovery related to policy and legal issues, PharmaSea will bring together practitioners, legal experts, policy advisors/makers and other stakeholders, focusing on the feasibility of harmonising, aligning and complementing current legal frameworks with recommendations and ready to use solutions tailored to marine biodiscovery.
Keywords
Biomaterial;
Bioactive compounds;
Drug discovery;
Bioprospecting;
Microbial communities;
Human health;
Genetic;
Human food;
Marine Region
76
Not associated to marine areas
0
Marine Region Map
